Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives
Since their introduction to pharmacotherapy, proton pump inhibitors (PPIs) have been widely used in the treatment of numerous diseases manifested by excessive secretion of gastric acid. Despite that, there are still unmet needs regarding their availability for patients of all age groups. Their poor...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/10/2043 |
| _version_ | 1797470354401132544 |
|---|---|
| author | Justyna Srebro Witold Brniak Aleksander Mendyk |
| author_facet | Justyna Srebro Witold Brniak Aleksander Mendyk |
| author_sort | Justyna Srebro |
| collection | DOAJ |
| description | Since their introduction to pharmacotherapy, proton pump inhibitors (PPIs) have been widely used in the treatment of numerous diseases manifested by excessive secretion of gastric acid. Despite that, there are still unmet needs regarding their availability for patients of all age groups. Their poor stability hinders the development of formulations in which dose can be easily adjusted. The aim of this review is to describe the discovery and development of PPIs, discuss formulation issues, and present the contemporary solutions, possibilities, and challenges in formulation development. The review outlines the physicochemical characteristics of PPIs, connects them with pharmacokinetic and pharmacodynamic properties, and describes the stability of PPIs, including the identification of the most important factors affecting them. Moreover, the possibilities for qualitative and quantitative analysis of PPIs are briefly depicted. This review also characterizes commercial preparations with PPIs available in the US and EU. The major part of the review is focused on the presentation of the state of the art in the development of novel formulations with PPIs covering various approaches employed in this process: nanoparticles, microparticles, minitablets, pellets, bilayer, floating, and mucoadhesive tablets, as well as parenteral, transdermal, and rectal preparations. It also anticipates further possibilities in the development of PPIs dosage forms. It is especially addressed to the researchers developing new formulations containing PPIs, since it covers the most important formulary issues that need to be considered before a decision on the selection of the formula is made. It may help in avoiding unnecessary efforts in this process and choosing the best approach. The review also presents an up-to-date database of publications focused on the pharmaceutical technology of formulations with PPIs. |
| first_indexed | 2024-03-09T19:35:23Z |
| format | Article |
| id | doaj.art-3546caf579db4324a453219ae0c676df |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T19:35:23Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-3546caf579db4324a453219ae0c676df2023-11-24T01:54:34ZengMDPI AGPharmaceutics1999-49232022-09-011410204310.3390/pharmaceutics14102043Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future PerspectivesJustyna Srebro0Witold Brniak1Aleksander Mendyk2Department of Pharmaceutical Technology and Biopharmaceutics, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Pharmaceutical Technology and Biopharmaceutics, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandDepartment of Pharmaceutical Technology and Biopharmaceutics, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, PolandSince their introduction to pharmacotherapy, proton pump inhibitors (PPIs) have been widely used in the treatment of numerous diseases manifested by excessive secretion of gastric acid. Despite that, there are still unmet needs regarding their availability for patients of all age groups. Their poor stability hinders the development of formulations in which dose can be easily adjusted. The aim of this review is to describe the discovery and development of PPIs, discuss formulation issues, and present the contemporary solutions, possibilities, and challenges in formulation development. The review outlines the physicochemical characteristics of PPIs, connects them with pharmacokinetic and pharmacodynamic properties, and describes the stability of PPIs, including the identification of the most important factors affecting them. Moreover, the possibilities for qualitative and quantitative analysis of PPIs are briefly depicted. This review also characterizes commercial preparations with PPIs available in the US and EU. The major part of the review is focused on the presentation of the state of the art in the development of novel formulations with PPIs covering various approaches employed in this process: nanoparticles, microparticles, minitablets, pellets, bilayer, floating, and mucoadhesive tablets, as well as parenteral, transdermal, and rectal preparations. It also anticipates further possibilities in the development of PPIs dosage forms. It is especially addressed to the researchers developing new formulations containing PPIs, since it covers the most important formulary issues that need to be considered before a decision on the selection of the formula is made. It may help in avoiding unnecessary efforts in this process and choosing the best approach. The review also presents an up-to-date database of publications focused on the pharmaceutical technology of formulations with PPIs.https://www.mdpi.com/1999-4923/14/10/2043proton pump inhibitorsdelayed-release tabletsenteric coatingEudragitomeprazolepantoprazole |
| spellingShingle | Justyna Srebro Witold Brniak Aleksander Mendyk Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives Pharmaceutics proton pump inhibitors delayed-release tablets enteric coating Eudragit omeprazole pantoprazole |
| title | Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives |
| title_full | Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives |
| title_fullStr | Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives |
| title_full_unstemmed | Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives |
| title_short | Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives |
| title_sort | formulation of dosage forms with proton pump inhibitors state of the art challenges and future perspectives |
| topic | proton pump inhibitors delayed-release tablets enteric coating Eudragit omeprazole pantoprazole |
| url | https://www.mdpi.com/1999-4923/14/10/2043 |
| work_keys_str_mv | AT justynasrebro formulationofdosageformswithprotonpumpinhibitorsstateoftheartchallengesandfutureperspectives AT witoldbrniak formulationofdosageformswithprotonpumpinhibitorsstateoftheartchallengesandfutureperspectives AT aleksandermendyk formulationofdosageformswithprotonpumpinhibitorsstateoftheartchallengesandfutureperspectives |